InvestorsObserver
×
News Home

Should You Buy Agile Therapeutics Inc (AGRX) Stock After it Has Gained 17.31% in a Week?

Thursday, August 31, 2023 10:08 AM | InvestorsObserver Analysts

Mentioned in this article

Should You Buy Agile Therapeutics Inc (AGRX) Stock After it Has Gained 17.31% in a Week?

Overall market sentiment has been high on Agile Therapeutics Inc (AGRX) stock lately. AGRX receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,bullish
Agile Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on AGRX!

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With AGRX Stock Today?

Agile Therapeutics Inc (AGRX) stock is trading at $2.44 as of 10:02 AM on Thursday, Aug 31, a rise of $0.22, or 9.87% from the previous closing price of $2.22. The stock has traded between $2.23 and $2.49 so far today. Volume today is light. So far 10,573 shares have traded compared to average volume of 41,560 shares. To see InvestorsObserver's Sentiment Score for Agile Therapeutics Inc click here.

More About Agile Therapeutics Inc

Agile Therapeutics Inc is a women's healthcare company to fulfill the unmet health needs of women. Its product candidates are designed to provide women with contraceptive options. The firm's initial product, Twirla, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. Click Here to get the full Stock Report for Agile Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App